Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“An important result from WCLC 2026 that could change clinical practice!
Presented at the IASLC, WCLC26 Presidential Symposium, the Phase III DESTINY-Lung04 trial may bring HER2-targeted therapy into the first-line setting for advanced HER2-mutant NSCLC.
In patients with previously untreated, advanced non-squamous NSCLC harboring HER2 (ERBB2) exon 19/20 mutations:
T-DXd (Enhertu) vs pembrolizumab + platinum/pemetrexed
- Median PFS: 14.3 vs 8.3 months
- HR 0.63 → 37% reduction in the risk of progression or death
- ORR: 70% vs 44.5%
- Median DoR: 13.4 vs 9.7 months
OS data are still immature, with no survival benefit demonstrated at this time. HER2 mutation is becoming an important determinant not only for later-line therapy, but also for first-line treatment selection in NSCLC.
These results once again highlight the importance of comprehensive molecular profiling/NGS at diagnosis.
You can also read:
